Similarly, neutralizing CD8+ or CD4+ T cells in orthotopic MOC2 mice abolished the therapeutic benefits of C‐P, i.e., the durability of tumor regression (Figure 3i; Figure S3h,i, Supporting Information). The gene discussed is CD8A; the disease is neoplasm.